Treats Parkinson’s disease (PD). ANDA 206153, held by Regcon Holdings. Rasagiline Mesylate.
As of Nov 21, 2026, ANDA 206153 (Rasagiline Mesylate), held by Regcon Holdings, was first approved by FDA on Oct 4, 2019, with 1 approved supplement and 0 published complete response letters.
Rasagiline tablets are indicated for the treatment of Parkinson’s disease (PD). Rasagiline tablets, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson's disease
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 4, 2019 | Original application | Approved | None posted |
| Rasagiline MesylateEQ 0.5MG BASE · tablet;oral | Rasagiline Mesylate | Rx |
| Rasagiline MesylateEQ 1MG BASE · tablet;oral | Rasagiline Mesylate | Rx |
| Jan 14, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 4, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters